StreetAlpha.app
Home › Stocks › MLYS

Mineralys Therapeutics, Inc. (MLYS)

Healthcare
$13.66
▼ −3.53%
LAST CLOSE · NOV 20

Mineralys Therapeutics develops lorundrostat, an oral medicine for high blood pressure that is hard to control with other treatments. It last closed at $13.66 on Nov 20, down 3.53% on the day. The next earnings report for MLYS is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, MLYS reported EPS of -$0.64. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months MLYS insiders bought $8.8M of stock on the open market and sold $71.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is MLYS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MLYS.

Key Stats

Last 12 months
Results
Net income
−$370.0M
EPS (diluted)
−$4.30
Valuation
Market cap
$1.2B
88.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$101.3M
At Sep 30
Debt
$100K
At Sep 30
Shareholder equity
$503.8M
Shares outstanding
88.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$29.8M−$29.8MFY2022FY2023: −$71.9M−$71.9MFY2023FY2024: −$177.8M−$177.8MFY2024FY2025: −$154.7M−$154.7MFY2025

From MLYS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$0.64
Quarter ended Sep 2026
Year ago EPS
-$0.52
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.98Dec '24Mar 2025: -$0.79Mar '25Jun 2025: -$0.66Jun '25Sep 2025: -$0.52Sep '25Dec 2025: -$0.35Dec '25Mar 2026: -$0.47Mar '26Jun 2026: -$2.85Jun '26Sep 2026: -$0.64Sep '26Latest -$0.64
Revenue by quarter
Not enough quarters on file yet.
How MLYS moved after its last 8 reports
Average move the session after a report ±4.3%
Nov 4, 2026After the close−10.3%
Aug 11, 2026After the close−1.0%
May 6, 2026After the close−2.6%
Mar 12, 2026After the close−3.0%
Nov 10, 2025After the close+5.9%
Aug 12, 2025After the close+0.4%
May 12, 2025After the close+1.2%
Feb 12, 2025Time not announced+10.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MLYSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MLYS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MLYS

Technical Analysis

MLYS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 21% below its 20 day and 55% below its 50 day average. It is 88% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $13.57, and the nearest resistance the Pivot at $14.01.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.2%/day
Key levels
$44.9952 week high+229.4%
$25.75200 day average+88.5%
$24.18100 day average+77.0%
$21.1250 day average+54.6%
$16.88Swing high (Nov 12)+23.6%
$16.5320 day average+21.0%
$14.44Pivot R1+5.7%
$14.01Pivot+2.6%
$13.66Last close
$13.5752 week low−0.7%
$13.22Pivot S1−3.2%
Indicators
RSI (14)28.67Oversold below 30Oversold
MACD-2.06Below its signal lineBearish
Stochastic4.2Near the bottom of its rangeOversold
ADX (14)26.7Trending down
Williams %R-97.8Oversold below −80, overbought above −20Oversold
CCI (20)-89.1Oversold below −100, overbought above 100Neutral
Rate of change−10.9%Change over 10 sessionsBearish
ATR (14)$1.26Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MLYS

What happened before

See how MLYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MLYS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MLYS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MLYSHow many large options trades hit MLYS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

MLYS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●115 buying vs 102 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding219226−3.1%
In funds' top 1079−22.2%
Held by funds110.9%113.5%−2.5 pts
New / increased32 / 8333 / 89−5.7%
Reduced / sold out64 / 3865 / 23+15.9%
Put/call ratio0.000.67−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MLYS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MLYS Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$8.8M1 buy · 1 insider
Sold$71.3M37 sales · 7 insiders
35% of the selling was under pre-arranged trading plans.
2026-01 sold $11.1M2026-02 sold $647K2026-03 bought $8.8M2026-03 sold $2.7M2026-04 sold $1.0M2026-05 sold $664K2026-06 sold $5.3M2026-07 sold $1.1M2026-08 sold $252K2026-09 sold $5.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 30Jon CongletonCEOSale plan75,000$25.46$1.9M
Sep 22Brian Taylor SlingsbyDirectorSale104,320$28.81$3.0M
Sep 21Eric WarrenChief Commercial OfficerSale plan7,438$28.12$209K
Sep 15Daphne KarydasDirectorSale plan3,000$28.58$86K
Aug 21Eric WarrenChief Commercial OfficerSale plan7,437$25.98$193K
Aug 10David Malcom RodmanChief Medical OfficerSale plan2,170$27.09$59K
Every insider buy and sale for MLYS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MLYS insider trades →

From SEC Form 4 filings by MLYS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLYS is in one of them and how their past MLYS trades turned out.

MLYS in the AI portfolios
Loading…

MLYS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MLYS in an article yet. Here's the latest on the wider market.

MLYS in the news

About Mineralys Therapeutics

Mineralys Therapeutics is a biopharmaceutical company based in Radnor, Pennsylvania, that develops medicines for diseases driven by high levels of aldosterone, a hormone that affects blood pressure. Its main product candidate, lorundrostat, is a pill taken by mouth that is being developed to treat high blood pressure, especially cases that do not respond fully to other treatments. The company is also studying lorundrostat in patients with chronic kidney disease and obstructive sleep apnea. Its target patients are adults with high blood pressure, and the company has not yet sold a product.

Headquarters
Radnor, PA